Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, almost 70% gains off bottom, but I was busy some-place else.
So that's why TELK went crazy.
ANR: +4%
That MS article will have helped.
They have, seems like there's a new rule saying beaten down stocks have to make up all of their losses in 2/3 sessions :)
Seen a few of those lately, with good results.:)
Seeking Alpha, sorry, I keep forgetting not everyone knows that acronym :)
http://seekingalpha.com/
Thanks, didn't know that. Shameless BS, nothing new here :)
Apparently it's getting a lot of SA love, so beware. The action is sweet, though.
Edit: volume off the charts now.
Quasi R/S:
JA Solar Holdings Co. Ltd. (NASDAQ: JASO) has announced that it will change the ratio of its American depositary shares to its ordinary shares from one ADS representing one ordinary share to a new ratio where one ADS will now represent five ordinary shares. In effect, this is a one-for-five reverse stock split.
I recall GS putting it on sell after the first reversal a few months ago. We're 50% higher now :) Just need some more encouraging sales data, from China too, that would certainly help.
Too many lol, what a feast:
http://finviz.com/screener.ashx?v=140&f=ind_stocksonly,sh_curvol_o50,sh_price_u50,sh_relvol_o0.75,ta_change_u3&ft=4&o=-change
Not seen so many at the same time in a while.
IVAN nHOD
ACUR nHOD
Indeed, nice support @ 3.60 Could be we stay range bounce 3.60-3.90 before the next leg up.
UNXL +40% now
Looking at the 5 minute chart, volume is very strong. Must be more than small fries :)
Some shake &n bake here, but off we go - again. At this rate could be we see $13. Volume is already hefty.
Sorry, wrong link. Found it on thefly:
http://www.theflyonthewall.com/permalinks/entry.php?symbol=anr
GPRC: +28%
Has an SA article over the weekend, could be reason.
JKS +12% gap up
STSI +7% in PM
Worth watching today.
AAPL in 525s in PM
Strong support here but if it fails, could get ugly.
Oxigene presents encouraging OXi4503 preclinical and clinical data
Lots of bio data today.
Oxigene announced that investigators at the University of Florida presented encouraging clinical data using Oxigene's vascular disrupting agent, or VDA, OXi4503, in patients with acute myelogenous leukemia, or AML, at the annual meeting of the American Society of Hematology in Atlanta, Georgia. The data showed responses and a manageable safety profile in this first-in-man trial of a VDA in AML. Overall response was 2/5, or 40%, with 1 patient achieving a marrow complete remission, or mCR, and 1 patient achieving a partial remission. The median number of cycles was 1, in a range of 1-6. Three of 5 subjects discontinued the study due to AML progression and one due to pneumonia. One patient with AML treated with 5 mg/m2 OXi4503 has received 6 months of treatment and continues to receive weekly infusions.
Definitely in play today, thx sbd.
PCLN down in PM on downgrade (wOP)
Dropped straight through the 200MA on that downgrade by DB. It had several occasions to break upwards, none successful. Follows Friday's decent drop.
priceline.com downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded priceline.com on expectations the company's 2013 will be more challenging due to intensifying competition. The firm lowered its price target for shares to $710 from $800.
CLDX up in PM on upgrade
Jefferies Lifts Target on Celldex Therapeutics ($CLDX) to $9 on Compelling CDX-011 OS Data
http://www.streetinsider.com/Analyst+Comments/Jefferies+Lifts+Target+on+Celldex+Therapeutics+(CLDX)+to+%249+on+Compelling+CDX-011+OS+Data/7934800.html
Geron presents positive results from Phase 2 study of Imetelstat
Up in PM.
Co announced positive clinical results from the Phase 2 trial of imetelstat, the company's first-in-class telomerase inhibitor, in patients with essential thrombocythemia (ET). The data, which showed rapid and durable hematologic and molecular responses in patients treated with imetelstat, were presented Sunday evening in an oral session at the 54th Annual Meeting of the American Society of Hematology in Atlanta, GA. The results from the first 14 patients enrolled in the ET study were reported. All were refractory to or intolerant of conventional therapies (hydroxyurea, anagrelide and/or interferon-alpha). Platelet counts were reduced in all patients (a 100% hematologic response rate) and normalized in 13 out of 14 patients (a 92.9% complete response rate). The allelic burden of the JAK2 V617F gene mutation decreased over time in the seven patients who had such a mutation, with substantial reductions that qualified as partial molecular responses achieved in six out of seven (85.7%) patients within three to six months of treatment with imetelstat. In the study, imetelstat was generally well tolerated. The majority of the non- hematologic adverse events were mild-to-moderate in severity, the most frequent being gastrointestinal events.
Met Coal prices expected to rally, says Morgan Stanley
WLT of course has already had a few good days on buyout rumours. Support at the 50MA.
Morgan Stanley expects met coal prices to rally due to lean inventories at Chinese steel companies. The firm expects met coal rices to rally in Q1 and reiterates its Overweight rating on Walter Energy (WLT) and and likes Alpha Natural for a tactical trade. Note that Goldman lowered its met coal price forecasts in a note today.
See what you mean, that was a nasty drop indeed. The pop to $46s, if we got it, would be purely technical, some bottom feeders etc. Like you say, worth watching in either direction - steep moves make for nice money.
Good to see you around again, Ken :)